相关实验视频
Updated: Sep 16, 2025

08:15
Gastrointestinal Motility Monitor GIMM
Published on: December 1, 2010
31.0K
GLP-1受体激动剂对胃肠道运动的影响
Danielle Bellavance1, Samantha Chua2, Hiroshi Mashimo3
1Department of Medicine, VA Boston Healthcare System, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Current gastroenterology reports
|July 7, 2025
概括
类似葡萄糖-1受体激动剂 (GLP-1RA) 显著影响胃肠机动性,影响其治疗效益和常见的副作用,如恶心和延迟胃排空.
科学领域:
- 胃肠病学 胃肠病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RA) 对糖尿病和肥胖有效.
- GLP-1 RAs模仿天然激素GLP-1,影响葡萄糖代谢和体重.
- 胃肠道 (GI) 运动的改变是GLP-1RA代谢效应的一个关键机制.
研究的目的:
- 审查GLP-1RA对胃肠道运动的生理影响.
- 为了突出这些运动变化的临床影响.
- 确定未来的研究方向.
主要方法:
- 对当前理解的文献综述.
- 对生理机制的分析.
- 临床证据的综合分析.
主要成果:
- GLP-1RA会影响整个肠道的运动性.
- 延迟胃排空是一个已有充分证据的效应.
- 改变运动能力会导致恶心,吐和过早腹等不良影响.
结论:
- GLP-1 RA诱导的肠道机动性变化是其作用和耐受性的核心.
- 临床影响包括志向风险和坚持挑战.
- 需要进一步的研究才能充分理解和管理这些影响.
相关概念视频
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
629
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
629
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
412
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
412
Glucagon-like Receptor Agonists
431
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
431
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
307
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
307
Gastrointestinal Motility Disorders
609
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
609
Drugs Affecting GI Tract Motility: Other Laxatives
471
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
471

